Literature DB >> 7486930

Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis.

D E Nix1, R Tyrrell, M Müller.   

Abstract

The pharmacodynamic effects of metronidazole on Trichomonas vaginalis have been poorly characterized. The present in vitro study was performed to characterize the relationship between killing of trichomonads and metronidazole exposure (metronidazole concentration and time of exposure). Five laboratory strains and five recent clinical isolates of T. vaginalis were studied. The minimum lethal concentrations (MLCs) of metronidazole for the strains ranged from 0.8 to 25 micrograms/ml under anaerobic conditions. Metronidazole exhibited concentration-dependent killing against T. vaginalis at concentrations ranging from 0.1 to > 10 times the MLC. The endpoint measurement, the kill rate constant, which was derived from the reduction in the logarithm of the colony count divided by exposure time, compared with the kill rate constant for the growth control was not affected by the time of assessment between 2 and 24 h. The kill rate constant-versus-metronidazole exposure curves were similar when concentration was expressed as a multiple of the MLC. There were no apparent differences between the clinical isolates and laboratory strains. These data suggest that peak metronidazole concentration and/or area under the plasma concentration-versus-time curve are the important pharmacodynamic parameters to be optimized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486930      PMCID: PMC162837          DOI: 10.1128/AAC.39.8.1848

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Single- and multiple-dose metronidazole kinetics.

Authors:  J C Jensen; R Gugler
Journal:  Clin Pharmacol Ther       Date:  1983-10       Impact factor: 6.875

2.  Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetus.

Authors:  J G Meingassner; H Mieth; R Czok; D G Lindmark; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

Review 3.  Treatment of sexually transmitted vaginosis/vaginitis.

Authors:  J G Lossick
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

4.  Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.

Authors:  J G Meingassner; J Thurner
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

5.  Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages.

Authors:  I Amon; K Amon; H Hüller
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-08

6.  Current therapy of vulvovaginitis.

Authors:  M F Rein
Journal:  Sex Transm Dis       Date:  1981 Oct-Dec       Impact factor: 2.830

7.  Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis.

Authors:  J N Krieger; C S Dickins; M F Rein
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis.

Authors:  J Lyng; J Christensen
Journal:  Acta Obstet Gynecol Scand       Date:  1981       Impact factor: 3.636

9.  In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis.

Authors:  M Müller; J G Lossick; T E Gorrell
Journal:  Sex Transm Dis       Date:  1988 Jan-Mar       Impact factor: 2.830

  9 in total
  10 in total

Review 1.  The economic potential of dual individualisation methodologies.

Authors:  J A Paladino; G S Zimmer; J J Schentag
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

2.  Calprotectin expression in vitro by oral epithelial cells confers resistance to infection by Porphyromonas gingivalis.

Authors:  K Nisapakultorn; K F Ross; M C Herzberg
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

3.  Food selectivity of anaerobic protists and direct evidence for methane production using carbon from prey bacteria by endosymbiotic methanogen.

Authors:  Yuga Hirakata; Masashi Hatamoto; Mamoru Oshiki; Takahiro Watari; Nobuo Araki; Takashi Yamaguchi
Journal:  ISME J       Date:  2020-04-27       Impact factor: 10.302

Review 4.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

5.  Cytopathogenic effect of Trichomonas vaginalis on human vaginal epithelial cells cultured in vitro.

Authors:  R O Gilbert; G Elia; D H Beach; S Klaessig; B N Singh
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.

Authors:  Kelly A Sprandel; Christopher A Schriever; Susan L Pendland; John P Quinn; Mark H Gotfried; Suzanne Hackett; Mary Beth Graham; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 7.  Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.

Authors:  Sarah L Cudmore; Kiera L Delgaty; Shannon F Hayward-McClelland; Dino P Petrin; Gary E Garber
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 10.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.